CN101132802A - 通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法 - Google Patents

通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法 Download PDF

Info

Publication number
CN101132802A
CN101132802A CNA2005800127675A CN200580012767A CN101132802A CN 101132802 A CN101132802 A CN 101132802A CN A2005800127675 A CNA2005800127675 A CN A2005800127675A CN 200580012767 A CN200580012767 A CN 200580012767A CN 101132802 A CN101132802 A CN 101132802A
Authority
CN
China
Prior art keywords
ampk
ischemia
apoplexy
pampk
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800127675A
Other languages
English (en)
Chinese (zh)
Inventor
L·D·麦库洛夫
H·李
J·麦克法丹
G·V·罗奈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Fasgen LLC
Original Assignee
Johns Hopkins University
Fasgen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Fasgen LLC filed Critical Johns Hopkins University
Publication of CN101132802A publication Critical patent/CN101132802A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2005800127675A 2004-03-24 2005-03-23 通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法 Pending CN101132802A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55600004P 2004-03-24 2004-03-24
US60/556,000 2004-03-24

Publications (1)

Publication Number Publication Date
CN101132802A true CN101132802A (zh) 2008-02-27

Family

ID=35056772

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800127675A Pending CN101132802A (zh) 2004-03-24 2005-03-23 通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法

Country Status (11)

Country Link
US (1) US8293791B2 (https=)
EP (1) EP1734973A4 (https=)
JP (1) JP2008504228A (https=)
KR (2) KR20070085093A (https=)
CN (1) CN101132802A (https=)
AU (1) AU2005226731A1 (https=)
BR (1) BRPI0509085A (https=)
CA (1) CA2560843A1 (https=)
IL (1) IL178242A0 (https=)
MX (1) MXPA06010916A (https=)
WO (1) WO2005092068A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119868551A (zh) * 2024-11-28 2025-04-25 四川大学华西医院 F-box蛋白48的抑制剂的新用途和治疗缺血性脑血管病的药物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.
KR101152607B1 (ko) 2005-12-20 2012-06-05 에스케이케미칼주식회사 ６-[４-(２-피페리딘-1-일-에톡시)-페닐]-３-피리딘-４-일-피라졸로[１,５-ａ]피리미딘의 제조방법
KR101787116B1 (ko) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
EP2978307B1 (en) 2013-03-28 2018-12-26 The Trustees of Columbia University in the City of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
KR101532211B1 (ko) * 2014-04-30 2015-06-30 세종대학교산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119868551A (zh) * 2024-11-28 2025-04-25 四川大学华西医院 F-box蛋白48的抑制剂的新用途和治疗缺血性脑血管病的药物

Also Published As

Publication number Publication date
KR20070085093A (ko) 2007-08-27
US20090137665A1 (en) 2009-05-28
MXPA06010916A (es) 2007-07-25
EP1734973A4 (en) 2010-08-04
JP2008504228A (ja) 2008-02-14
EP1734973A2 (en) 2006-12-27
AU2005226731A1 (en) 2005-10-06
WO2005092068A2 (en) 2005-10-06
KR101283416B1 (ko) 2013-07-08
BRPI0509085A (pt) 2007-08-21
IL178242A0 (en) 2007-03-08
US8293791B2 (en) 2012-10-23
KR20120078756A (ko) 2012-07-10
CA2560843A1 (en) 2005-10-06
WO2005092068A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
McCullough et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke
Cao et al. Curcumin ameliorates oxidative stress-induced intestinal barrier injury and mitochondrial damage by promoting Parkin dependent mitophagy through AMPK-TFEB signal pathway
Sheikh-Hamad et al. p38 kinase activity is essential for osmotic induction of mRNAs for HSP70 and transporter for organic solute betaine in Madin-Darby canine kidney cells
Bao et al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat
Edwards et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation
Jornada et al. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania
Raval et al. ɛPKC phosphorylates the mitochondrial K+ ATP channel during induction of ischemic preconditioning in the rat hippocampus
US12053454B2 (en) Compositions for cryopreservation and methods of use thereof
Damaraju et al. Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes
Loganathan et al. Effects of soluble guanylate cyclase activation on heart transplantation in a rat model
CN101132802A (zh) 通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法
Hong et al. A novel role of lactate: Promotion of Akt-dependent elongation of microglial process
Gonzalez-Cabo et al. Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency
Young et al. Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer
Dienel et al. Imaging brain activation: simple pictures of complex biology
Yu-liang et al. Effects of adenosine metabolism in astrocytes on central nervous system oxygen toxicity
EP2364698A2 (en) Composition for control of aging and / or extension of life, containing dapsone as active ingredient
Ciocci Pardo et al. Myocardial and mitochondrial effects of the anhydrase carbonic inhibitor ethoxzolamide in ischemia‐reperfusion
Durham et al. Altered malate dehydrogenase activity in nucleus magnocellularis of the chicken following cochlea removal
Anderson et al. Inhibition of contraction of isolated lymphatic ducts by atrial natriuretic peptide
Martínez et al. The human deferential artery: endothelium-mediated contraction in response to adrenergic stimulation
HK1118217A (en) Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
Steiner et al. Role of the preoptic carbon monoxide pathway in endotoxin fever in rats
Liu et al. Quantitative In Silico Analysis of the Arrhythmogenic CaMKII-Sodium-Calcium-CaMKII Feedback in the Failing Rabbit Ventricular Myocyte
JP2007529549A (ja) 神経エネルギーバランスを変化させることによる摂食行動の制御

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1118217

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080227

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1118217

Country of ref document: HK